BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/22/2023 11:25:51 AM | Browse: 59 | Download: 114
 |
Received |
|
2023-05-19 14:12 |
|
Peer-Review Started |
|
2023-05-19 14:15 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-07-19 08:22 |
|
Revised |
|
2023-07-26 18:42 |
|
Second Decision |
|
2023-09-26 02:52 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-09-26 08:40 |
|
Articles in Press |
|
2023-09-26 08:40 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-12-19 00:44 |
|
Publish the Manuscript Online |
|
2023-12-22 11:25 |
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Effectiveness and safety of apixaban and rivaroxaban vs warfarin in patients with atrial fibrillation and chronic kidney disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sylvie Perreault, Laurie-Anne Boivin Proulx, Aurélie Terrier-Lenglet, Ziad A Massy and Marc Dorais |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sylvie Perreault, BPharm, MSc, PhD, Professor, Faculty of Pharmacy, University of Montreal, No. 2940 Chemin de Polytechnique, Montreal H3C3J7, Quebec, Canada. sylvie.perreault@umontreal.ca |
| Key Words |
Atrial fibrillation; Chronic kidney disease; Direct oral anticoagulant; Effectiveness; Safety; Warfarin |
| Core Tip |
Compared to warfarin, rivaroxaban and apixaban appear to be effective and safe in atrial fibrillation patients with stage III chronic kidney disease (CKD) in real world. Rivaroxaban 15 mg and 20 mg presented a similar effectiveness and safety composite risk. However, apixaban 2.5 mg might even have a better safety profile than warfarin, while apixaban 5.0 mg might have a better effectiveness profile than warfarin, to a reduction in deaths. Appropriately sized randomized controlled trials are needed to confirm these findings in stage III CKD patients. |
| Publish Date |
2023-12-22 11:25 |
| Citation |
Perreault S, Boivin Proulx LA, Lenglet A, Massy ZA, Dorais M. Effectiveness and safety of apixaban and rivaroxaban vs warfarin in patients with atrial fibrillation and chronic kidney disease. World J Nephrol 2023; 12(5): 132-146 |
| URL |
https://www.wjgnet.com/2220-6124/full/v12/i5/132.htm |
| DOI |
https://dx.doi.org/10.5527/wjn.v12.i5.132 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
